Ifm_05-may 2022 May 2026

Patients are encouraged to discuss the balance between disease control and the toxic long-term effects of maintenance drugs with their oncology team.

Lenalidomide was the primary drug used for maintenance in this study. Key Findings: IFM_05-May 2022

A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects. Patients are encouraged to discuss the balance between

One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations IFM_05-May 2022

To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods.

The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment.